CSF proteins of inflammation, proteolysis and lipid transport define preclinical AD and progression to AD dementia in cognitively unimpaired individuals

This preclinical AD CSF proteome study identified a panel of 12-CSF markers detecting amyloid positivity and clinical progression to AD with high accuracy; some of these CSF proteins related to immune function, neurotrophic processes, energy metabolism and endolysosomal functioning (e.g., ITGB2, CLE...

Full description

Saved in:
Bibliographic Details
Published inMolecular neurodegeneration Vol. 19; no. 1; pp. 82 - 5
Main Authors Del Campo, Marta, Quesada, Carlos, Vermunt, Lisa, Peeters, Carel F W, Hok-A-Hin, Yanaika S, Trieu, Calvin, Braber, Anouk den, Verberk, Inge M W, Visser, Pieter J, Tijms, Betty M, van der Flier, Wiesje M, Teunissen, Charlotte E
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 11.11.2024
BioMed Central
BMC
Subjects
Advertising executives
Aged
Alzheimer Disease - cerebrospinal fluid
Alzheimer Disease - metabolism
Biomarkers - cerebrospinal fluid
Cerebrospinal fluid proteins
Disease Progression
Female
Humans
Inflammation - metabolism
Letter to the Editor
Male
Middle Aged
Proteolysis
Proteome - metabolism
Online AccessGet full text

Cover

More Information
Summary:This preclinical AD CSF proteome study identified a panel of 12-CSF markers detecting amyloid positivity and clinical progression to AD with high accuracy; some of these CSF proteins related to immune function, neurotrophic processes, energy metabolism and endolysosomal functioning (e.g., ITGB2, CLEC5A, IGFBP-1, CST3) changed before amyloid positivity is established.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Correspondence-3
content type line 23
ISSN:1750-1326
1750-1326
DOI:10.1186/s13024-024-00767-z